Peter Foley

Skin & Cancer Foundation Inc

A/Prof Foley currently holds the position of Associate Professor, Department of Medicine (Dermatology) at The University of Melbourne, Director of Research at the Skin & Cancer Foundation Inc, and is a visiting dermatologist at the Photobiology, Phototherapy and Biologics Clincs and St. Vincent's Hospital Melbourne and the Phototherapy and Biologics Clinics at the Skin & Cancer Foundation Inc.

 

As Director of Research, A/Prof Foley directs the Foundation's rapidly expanding clinical trials program and the Australasian Psoriasis Registry. He has well over 60 peer-reviewed publications and has been an investigator in over 50 clinical trials.



E-Posters by Peter Foley
Durability of response in plaque psoriasis patients receiving certolizumab pegol over 48 Weeks in phase 3 studies: CIMPASI-1, CIMPASI-2, CIMPACT
Durability of response in plaque psoriasis patients receiving certolizumab pegol over 48 Weeks in phase 3 studies: CIMPASI-1, CIMPASI-2, CIMPACT
Mattias Augustin, Jolanta Węgłowska, Mark Lebwohl, Carle Paul, Vincent Piguet, Howard Sofen, Andrew Blauvelt, Luke Peterson, Robert Rolleri, Kristian Reich, Diamant Thaçi, Craig Leonardi, Yves Poulin, Catherine Arendt, Alice B. Gottlieb
Secukinumab treated patients in the Australian clinical practice setting: HOPE study investigating the quality of life in patients with severe chronic plaque psoriasis after treatment
Secukinumab treated patients in the Australian clinical practice setting: HOPE study investigating the quality of life in patients with severe chronic plaque psoriasis after treatment
Peter Foley, Meagan Walsh, Eric Mate
Certolizumab pegol is effective for plaque psoriasis across patient subgroups
Certolizumab pegol is effective for plaque psoriasis across patient subgroups
Kristian Reich, Andrew Blauvelt, Diamant Thaçi, Craig Leonardi, Yves Poulin, Daniel Burge, Luke Peterson, Catherine Arendt, Alice B. Gottlieb